Dr. Hamid Ghandehari is Awarded NIH STTR Phase II Grant
RECOGNITION, RESEARCH
Jun 27, 2017

Dr. Hamid Ghandehari is Awarded NIH STTR Phase II Grant

Dr. Ghandehari was awarded a NIH STTR Phase II grant in collaboration with a local company, TheraTarget, Inc. The project is "In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma". Total costs of the grant are $1,401,869... Read More

Archives by Year